Genus（GNS）株式概要
ジーナス社は、北米、中南米、英国、その他のヨーロッパ、中東、ロシア、アフリカ、アジアの農家向けに動物遺伝子を生産・販売している。 詳細
GNS Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Genus plc 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | UK£21.98 |
| 52週高値 | UK£32.29 |
| 52週安値 | UK£18.90 |
| ベータ | 0.90 |
| 1ヶ月の変化 | -7.02% |
| 3ヶ月変化 | -14.64% |
| 1年変化 | 13.89% |
| 3年間の変化 | -3.68% |
| 5年間の変化 | -55.88% |
| IPOからの変化 | 1,528.15% |
最新ニュース
ナラティブの更新 • Jun 05
GNS: Margin Discipline And Stable P/E Framework Will Drive Medium Term Upside
Genus’s analyst price target holds steady at £37.00 as analysts balance a modestly lower revenue growth outlook with slightly higher profit margin and P/E assumptions following mixed new coverage from JPMorgan and BNP Paribas. Analyst Commentary Recent research coverage has focused on how Genus’s current valuation lines up with its profit potential, with one new initiation from JPMorgan and another neutral initiation helping anchor the £37.00 analyst price target.
ナラティブの更新 • May 18
GNS: Bullish JPMorgan Initiation And Margin Outlook Will Drive Medium Term Upside
Analysts have reduced their fair value estimate for Genus from about £31.63 to roughly £31.28. This reflects a combination of slightly softer revenue growth assumptions, a modestly higher discount rate, and expectations for a stronger profit margin profile supported by a mix of bullish and neutral recent research views.ナラティブの更新 • May 03
GNS: China Joint Venture Cash Inflow Will Drive Medium Term Upside
Analysts have kept the Genus fair value target steady at £37.00, while modestly adjusting underlying assumptions on discount rate, profit margin and future P/E to reflect a mix of bullish and neutral initiation views in recent research. Analyst Commentary Recent initiation coverage signals a mixed but generally constructive tone on Genus, with one major bank expressing clear optimism and others adopting a more neutral stance.ナラティブの更新 • Apr 19
GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside
Analysts have lifted their fair value estimate for Genus from £35.00 to £37.00, citing updated assumptions on discount rates, growth, margins, and future P/E multiples reflected in recent Street research, including the £1.00 price target increase reported by Berenberg. Analyst Commentary Recent Street research on Genus points to a more constructive tone on the shares, with bullish analysts reflecting this in higher price targets and refreshed valuation work.
ナラティブの更新 • Apr 04
GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside
Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.ナラティブの更新 • Mar 20
GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside
Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.Recent updates
ナラティブの更新 • Jun 05
GNS: Margin Discipline And Stable P/E Framework Will Drive Medium Term Upside
Genus’s analyst price target holds steady at £37.00 as analysts balance a modestly lower revenue growth outlook with slightly higher profit margin and P/E assumptions following mixed new coverage from JPMorgan and BNP Paribas. Analyst Commentary Recent research coverage has focused on how Genus’s current valuation lines up with its profit potential, with one new initiation from JPMorgan and another neutral initiation helping anchor the £37.00 analyst price target.ナラティブの更新 • May 18
GNS: Bullish JPMorgan Initiation And Margin Outlook Will Drive Medium Term Upside
Analysts have reduced their fair value estimate for Genus from about £31.63 to roughly £31.28. This reflects a combination of slightly softer revenue growth assumptions, a modestly higher discount rate, and expectations for a stronger profit margin profile supported by a mix of bullish and neutral recent research views.ナラティブの更新 • May 03
GNS: China Joint Venture Cash Inflow Will Drive Medium Term Upside
Analysts have kept the Genus fair value target steady at £37.00, while modestly adjusting underlying assumptions on discount rate, profit margin and future P/E to reflect a mix of bullish and neutral initiation views in recent research. Analyst Commentary Recent initiation coverage signals a mixed but generally constructive tone on Genus, with one major bank expressing clear optimism and others adopting a more neutral stance.ナラティブの更新 • Apr 19
GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside
Analysts have lifted their fair value estimate for Genus from £35.00 to £37.00, citing updated assumptions on discount rates, growth, margins, and future P/E multiples reflected in recent Street research, including the £1.00 price target increase reported by Berenberg. Analyst Commentary Recent Street research on Genus points to a more constructive tone on the shares, with bullish analysts reflecting this in higher price targets and refreshed valuation work.ナラティブの更新 • Apr 04
GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside
Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.ナラティブの更新 • Mar 20
GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside
Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.ナラティブの更新 • Mar 06
GNS: China JV And Gene Editing Progress Will Support Medium Term Upside
Analysts have raised their price target on Genus by £1.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Analysts lifting their fair value assumptions for Genus are signalling a shift in how they view the balance between the company’s growth potential and execution risks.ナラティブの更新 • Feb 20
GNS: Gene Editing Execution And Regulatory Timelines Will Constrain Medium-Term Upside
Analysts have raised their fair value estimate for Genus from £24.00 to £25.50, reflecting updated assumptions on revenue growth, profit margins and the potential of its gene editing technology as highlighted in recent research. Analyst Commentary Recent street research on Genus highlights a mix of optimism around its gene editing platform and caution around how that potential is reflected in the share price.ナラティブの更新 • Feb 06
GNS: Gene Editing Progress And China JV Will Shape Balanced Medium Term Outlook
Genus's updated analyst price target reflects a modest uplift in estimated fair value to £30.82, supported by higher assumed revenue growth and a richer future P/E multiple, even as analysts factor in a slightly higher discount rate and softer profit margins. Analyst Commentary Recent Street research on Genus points to a generally constructive stance, with analysts revisiting their models and price targets as they reassess the company’s growth potential and execution risks.ナラティブの更新 • Jan 23
GNS: Gene Editing Breakthrough Will Drive Medium Term Upside Potential
Narrative Update on Genus Analysts have lifted their price target on Genus to £31.00 from £29.00, citing the company's gene editing technology and its perceived medium term upside potential as key reasons for the change. Analyst Commentary Bullish analysts are highlighting Genus as a name with medium term upside potential, underpinned by its gene editing capabilities and recent supportive price target work.ナラティブの更新 • Jan 08
GNS: Gene Editing Potential Will Drive Balanced Medium-Term Opportunity And Execution Risk
Narrative Update Analysts now see Genus as fairly valued in a range of £30.50 to £31.00. This reflects a modestly revised P/E assumption, slightly higher revenue growth and profit margin expectations, and a growing focus on the potential of its gene editing technology for medium term upside.分析記事 • Jan 06
Calculating The Fair Value Of Genus plc (LON:GNS)
Key Insights Genus' estimated fair value is UK£21.95 based on 2 Stage Free Cash Flow to Equity Current share price of...ナラティブの更新 • Dec 22
GNS: Gene Editing Platform Will Shape Balanced Medium-Term Upside And Execution Risks
Genus's analyst price target has been raised from about £18.80 to £24.00 per share as analysts highlight the upside from its gene editing platform and reaffirm Buy ratings alongside recent target hikes from major banks. Analyst Commentary Recent research updates underscore a constructive stance on Genus, with buy ratings supported by the view that its gene editing platform could materially expand medium term earnings power.ナラティブの更新 • Dec 08
GNS: Gene Editing Platform Will Drive Medium Term Upside Despite Execution Risks
Analysts have nudged their price target on Genus higher to £31.00 from £29.00, citing increasing confidence in the medium term upside from its gene editing platform and a modest uplift in expected profitability, even as growth assumptions normalize slightly. Analyst Commentary Bullish analysts highlight that the uplift in price targets reflects growing conviction that Genus can translate its gene editing capabilities into sustained, above-market earnings growth over the medium term.ナラティブの更新 • Nov 24
GNS: Future China Joint Venture Will Improve Near-Term Shareholder Returns
Analysts have increased their price target for Genus from £29.00 to £31.00. This reflects greater confidence in the company's outlook despite moderating growth forecasts and a slightly higher discount rate.分析記事 • Nov 15
Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price
You may think that with a price-to-sales (or "P/S") ratio of 2.4x Genus plc ( LON:GNS ) is definitely a stock worth...分析記事 • Oct 28
Genus (LON:GNS) Is Paying Out A Dividend Of £0.217
Genus plc's ( LON:GNS ) investors are due to receive a payment of £0.217 per share on 5th of December. Including this...分析記事 • Oct 18
We Like Genus' (LON:GNS) Earnings For More Than Just Statutory Profit
Genus plc's ( LON:GNS ) solid earnings announcement recently didn't do much to the stock price. Our analysis suggests...分析記事 • Oct 11
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217
Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.217 per share on the 5th of December. This means...ナラティブの更新 • Sep 10
FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream
The upward revision in Genus’s price target reflects improved analyst expectations, driven by notable increases in both forecast revenue growth (from 4.0% to 4.9% per annum) and net profit margin (from 7.88% to 8.73%), resulting in a new fair value of £27.97. What's in the News Genus and Beijing Capital Agribusiness Co. (BCA) have accelerated the formation of a Chinese joint venture to commercialise PRRS 2 Resistant Pig (PRP), with BCA holding 51% and Genus 49%.分析記事 • Sep 07
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217
The board of Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.217 per share on the 5th of...分析記事 • Jul 25
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise
Despite an already strong run, Genus plc ( LON:GNS ) shares have been powering on, with a gain of 25% in the last...分析記事 • Jul 22
Estimating The Fair Value Of Genus plc (LON:GNS)
Key Insights The projected fair value for Genus is UK£25.58 based on 2 Stage Free Cash Flow to Equity Genus' UK£24.10...分析記事 • May 10
Genus plc (LON:GNS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry
Genus plc ( LON:GNS ) shareholders would be excited to see that the share price has had a great month, posting a 36...分析記事 • Apr 18
An Intrinsic Calculation For Genus plc (LON:GNS) Suggests It's 21% Undervalued
Key Insights The projected fair value for Genus is UK£20.55 based on 2 Stage Free Cash Flow to Equity Genus is...
新しいナラティブ • Feb 11
Regulatory Approvals And Sustainability Initiatives Will Strengthen Future Market Position
Expansion in the porcine business and PRRS resistant pig commercialization boosts revenue stability and growth through innovation and market penetration.分析記事 • Feb 01
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise
Genus plc ( LON:GNS ) shareholders are no doubt pleased to see that the share price has bounced 25% in the last month...分析記事 • Nov 20
Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S
Genus plc's ( LON:GNS ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a strong buy right now compared...分析記事 • Oct 23
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217
Genus plc ( LON:GNS ) will pay a dividend of £0.217 on the 6th of December. This payment means the dividend yield will...分析記事 • Oct 22
There May Be Some Bright Spots In Genus' (LON:GNS) Earnings
The market for Genus plc's ( LON:GNS ) shares didn't move much after it posted weak earnings recently. We did some...分析記事 • Sep 08
Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next
Genus plc ( LON:GNS ) shareholders are probably feeling a little disappointed, since its shares fell 4.1% to UK£17.10...分析記事 • Jun 16
The Price Is Right For Genus plc (LON:GNS)
Genus plc's ( LON:GNS ) price-to-earnings (or "P/E") ratio of 33.6x might make it look like a strong sell right now...分析記事 • Apr 20
Estimating The Fair Value Of Genus plc (LON:GNS)
Key Insights Genus' estimated fair value is UK£18.59 based on 2 Stage Free Cash Flow to Equity Genus' UK£17.18 share...分析記事 • Mar 25
Is Genus (LON:GNS) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Mar 05
With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For
Genus plc ( LON:GNS ) shares have had a horrible month, losing 26% after a relatively good period beforehand. The drop...分析記事 • Feb 25
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103
Genus plc ( LON:GNS ) has announced that it will pay a dividend of £0.103 per share on the 28th of March. The dividend...分析記事 • Jan 17
Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult
Genus plc's ( LON:GNS ) price-to-earnings (or "P/E") ratio of 44x might make it look like a strong sell right now...分析記事 • Dec 10
Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?
Key Insights The projected fair value for Genus is UK£15.63 based on 2 Stage Free Cash Flow to Equity Genus is...株主還元
| GNS | GB Biotechs | GB 市場 | |
|---|---|---|---|
| 7D | 4.0% | 3.7% | 2.4% |
| 1Y | 13.9% | 23.8% | 18.2% |
業界別リターン: GNS過去 1 年間で23.8 % の収益を上げたUK Biotechs業界を下回りました。
リターン対市場: GNSは、過去 1 年間で18.2 % のリターンを上げたUK市場を下回りました。
価格変動
| GNS volatility | |
|---|---|
| GNS Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 3.1% |
安定した株価: GNS 、 UK市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: GNSの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1994 | 3,190 | JK Kokke | www.genusplc.com |
ジーナス社は、北米、中南米、英国、その他のヨーロッパ、中東、ロシア、アフリカ、アジアの農家向けに動物遺伝子を生産・販売している。同社は3つのセグメントで事業を展開している：ジーナスPIC、ジーナスABS、ジーナス研究開発。ジーナスとボベックのブランドで乳牛と肉牛の精液と胚を、PICのブランドで繁殖豚と精液、技術サービスとアドバイスを提供している。同社は1994年に法人化され、イギリスのベイジングストークを拠点としている。
Genus plc 基礎のまとめ
| GNS 基礎統計学 | |
|---|---|
| 時価総額 | UK£1.47b |
| 収益（TTM） | UK£47.50m |
| 売上高(TTM) | UK£672.00m |
31.0x
PER（株価収益率2.2x
P/SレシオGNS は割高か？
公正価値と評価分析を参照収益と収入
| GNS 損益計算書（TTM） | |
|---|---|
| 収益 | UK£672.00m |
| 売上原価 | UK£402.40m |
| 売上総利益 | UK£269.60m |
| その他の費用 | UK£222.10m |
| 収益 | UK£47.50m |
直近の収益報告
Dec 31, 2025
次回決算日
Sep 10, 2026
| 一株当たり利益（EPS） | 0.71 |
| グロス・マージン | 40.12% |
| 純利益率 | 7.07% |
| 有利子負債／自己資本比率 | 46.4% |
GNS の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
1.5%
現在の配当利回り46%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/17 14:55 |
| 終値 | 2026/06/17 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/06/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Genus plc 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18
| アナリスト | 機関 |
|---|---|
| Robert Chantry | Berenberg |
| Matthew Lloyd | BNP Paribas |
| Alexander Jones | BofA Global Research |